Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2001

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma nork Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K

Argitaratua 2001

Journal article

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma nork Croucher, P, Shipman, C, Perry, M, Lippitt, J, Asosingh, K, van Beek, E, Van Camp, B, Russell, R, Dunstan, C, Vanderkerken, K

Antzeko izenburuak